Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. MicroRNA Biomarkers in IBD-Differential Diagnosis and Prediction of Colitis-Associated Cancer

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Triage May Improve Selection to Colonoscopy and Reduce the Number of Unnecessary Colonoscopies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Menstrual Pattern, Reproductive Hormones and Transabdominal 3D Ultrasound in 317 Adolescent Girls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Previous reports have shown that the proteomic markers apolipoprotein A1, hepcidin, transferrin, inter-alpha trypsin IV internal fragment, transthyretin, connective-tissue activating protein 3 and beta-2 microglobulin may discriminate between a benign pelvic mass and ovarian cancer (OC). The aim was to determine if these serum proteomic biomarkers alone as well as in combination with age and serum CA125, could be helpful in triage of women with a pelvic mass.
OriginalsprogEngelsk
TidsskriftGynecologic Oncology
Vol/bind123
Udgave nummer2
Sider (fra-til)308-13
Antal sider6
ISSN0090-8258
DOI
StatusUdgivet - 2011

ID: 33230114